The Role of Interleukin-33 in Head and Neck Squamous Cell Carcinoma Is Determined by Its Cellular Sources in the Tumor Microenvironment

Liang Peng, Wei‐Zen Sun, Lin Chen, Weiping WenFrontiers in Oncology 2021 · DOI

Abstract

According to the different sources of IL-33 in LSCC and OCSCC, we propose a hypothesis that stroma-derived IL-33 could favor tumor progression, while epithelial-derived IL-33 could favor antitumor immune responses in HNSCC.

Introduction

Head and Neck Squamous Cell Carcinoma (HNSCC) is a highly heterogeneous group of malignancies arising from various anatomical sites, including the larynx, oral cavity, and oropharynx. This heterogeneity often leads to inconsistent clinical outcomes and responses to therapy. Interleukin-33 (IL-33), a member of the IL-1 family, functions as an "alarmin" released upon cellular damage. Its role in cancer remains controversial, with evidence suggesting both pro-tumorigenic and anti-tumorigenic functions depending on the biological context. This study investigates whether the specific cellular source of IL-33 within the tumor microenvironment (TME) determines its functional impact in HNSCC.

Methodology

The researchers conducted a comprehensive bioinformatic analysis using data from The Cancer Genome Atlas (TCGA), accessed via cBioPortal. The cohort included 520 HNSCC cases with available mRNA-seq and clinical data.

Key techniques included:

  • TME Deconvolution: The xCell tool was utilized to estimate the abundance of 64 immune and stromal cell types from bulk RNA-seq data based on gene expression signatures.
  • Statistical Analysis: Pearson’s partial correlation tests identified cell types associated with IL-33 expression. Pathway enrichment was performed using KEGG and DAVID platforms.
  • Survival Analysis: Kaplan-Meier curves and log-rank tests evaluated the prognostic significance of IL-33 across different HNSCC subsites.

Results

Site-Specific Prognostic Value of IL-33

The study found that the prognostic impact of IL-33 is highly dependent on the primary tumor site. In the whole HNSCC cohort, IL-33 expression showed no significant correlation with overall survival. However, subsite analysis revealed striking differences. In laryngeal cancer (LSCC), high IL-33 expression was an unfavorable prognostic factor (p = 0.051), particularly after adjusting for tumor stage. Conversely, in oral cavity cancer (OCSCC), high IL-33 expression showed a trend toward improved survival.

Figure 6: Kaplan-Meier survival analysis of HNSCC patients stratified by IL-33 expression levels across the whole cohort (A), larynx (B), oropharynx (C), and oral cavity (D) subgroups.

The "Source Hypothesis" and Immune Landscape

The researchers propose that the divergent roles of IL-33 stem from its cellular origin. In LSCC, IL-33 was primarily linked to endothelial cells (a stromal source), correlating with pathways involved in cell cycle progression and tumor invasion. In OCSCC, IL-33 was derived from both epithelial and endothelial sources, correlating with robust anti-tumor immune signatures.

Analysis of the immune landscape showed that high IL-33 levels across HNSCC were generally associated with increased infiltration of various immune cells, such as CD8+ T cells and Dendritic Cells, and higher expression of immune checkpoint markers, including PD-1, PD-L1, and CTLA-4.

Figure 4: Comparison of immune cell infiltration (xCell scores) and immune checkpoint expression between high and low IL-33 expression groups.

Discussion and Future Directions

These findings resolve long-standing contradictions regarding IL-33 in HNSCC by highlighting the importance of tumor subsite and cellular source. Stroma-derived IL-33 appears to promote tumor progression, whereas epithelial-derived IL-33 may act as an alarmin to recruit anti-tumor immune effectors.

While this bioinformatic study provides strong correlative evidence, it is limited by the use of mRNA levels rather than protein activity and the inherent limitations of bulk tissue deconvolution. Future research using single-cell RNA sequencing and experimental models is necessary to validate the "Source Hypothesis" and explore the potential of IL-33 as a site-specific biomarker or therapeutic target in HNSCC.

Summary updated

Abstract

According to the different sources of IL-33 in LSCC and OCSCC, we propose a hypothesis that stroma-derived IL-33 could favor tumor progression, while epithelial-derived IL-33 could favor antitumor immune responses in HNSCC.
BibTeX
@inproceedings{peng2021role,
  author = {Liang Peng and Wei‐Zen Sun and Lin Chen and Weiping Wen},
  title = {{The Role of Interleukin-33 in Head and Neck Squamous Cell Carcinoma Is Determined by Its Cellular Sources in the Tumor Microenvironment}},
  booktitle = {Frontiers in Oncology},
  year = {2021},
  doi = {10.3389/fonc.2020.588454},
}
Figure